Question 1

What is Trastuzumab Deruxtecan used for?

Accepted Answer

Trastuzumab Deruxtecan (brand name Enhertu) is a Antibody-Drug Conjugate indicated for HER2+ Breast Cancer, HER2-low Breast Cancer, HER2+ Gastric Cancer.

Question 2

How does Trastuzumab Deruxtecan work?

Accepted Answer

Trastuzumab Deruxtecan works through the following mechanism: HER2-directed antibody-drug conjugate (ADC) that delivers a topoisomerase I inhibitor payload directly to HER2-expressing tumor cells..

Question 3

What are the most common side effects of Trastuzumab Deruxtecan?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for Trastuzumab Deruxtecan. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is Trastuzumab Deruxtecan the same as Enhertu?

Accepted Answer

Enhertu is a brand name for Trastuzumab Deruxtecan. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

Trastuzumab Deruxtecan

Mechanism of Action

Indications

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations